

ARENA PHARMACEUTICALS INC  
 Form 3  
 July 13, 2015

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â Bielasz Jennifer Kathleen (Last) (First) (Middle)	2. Date of Event Requiring Statement (Month/Day/Year) 07/10/2015	3. Issuer Name and Ticker or Trading Symbol ARENA PHARMACEUTICALS INC [ARNA]	4. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) VP, Accounting & Controller	5. If Amendment, Date Original Filed(Month/Day/Year)
---	--	---	---	--

C/O ARENA PHARMACEUTICALS, INC., Â 6154 NANCY RIDGE DRIVE  
 (Street)

SAN DIEGO, Â CA Â 92121  
 (City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,256	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security	4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---------------------------	----------------------	--

Edgar Filing: ARENA PHARMACEUTICALS INC - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Option (right to buy)	Â (1)	01/20/2016	Common Stock	3,000	\$ 16.8	D	Â
Employee Stock Option (right to buy)	Â (2)	07/28/2016	Common Stock	4,000	\$ 10.52	D	Â
Employee Stock Option (right to buy)	Â (3)	02/26/2017	Common Stock	6,500	\$ 13.5	D	Â
Employee Stock Option (right to buy)	Â (4)	03/17/2019	Common Stock	3,000	\$ 4.01	D	Â
Employee Stock Option (right to buy)	Â (5)	03/17/2020	Common Stock	4,500	\$ 3.25	D	Â
Employee Stock Option (right to buy)	Â (6)	03/19/2022	Common Stock	10,000	\$ 1.81	D	Â
Employee Stock Option (right to buy)	Â (7)	03/05/2020	Common Stock	24,000	\$ 8.54	D	Â
Employee Stock Option (right to buy)	Â (8)	03/03/2021	Common Stock	40,000	\$ 6.8	D	Â
Employee Stock Option (right to buy)	Â (9)	03/11/2022	Common Stock	60,000	\$ 4.47	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Bielasz Jennifer Kathleen C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO, CA 92121	Â	Â	Â VP, Accounting & Controller	Â

## Signatures

Adam S. Chinnock, as  
Attorney-in-Fact

07/13/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The options vested and became exercisable in four equal annual installments beginning on January 20, 2007.

(2) The options vested and became exercisable in four equal annual installments beginning on July 28, 2007.

## Edgar Filing: ARENA PHARMACEUTICALS INC - Form 3

- (3) The options vested and became exercisable in four equal annual installments beginning on February 26, 2008.
- (4) The options originally for a total of 6,000 shares vested and became exercisable in four equal annual installments beginning on March 17, 2010.
- (5) The options originally for a total of 9,000 shares vested and became exercisable in four equal annual installments beginning on March 17, 2011.
- The options originally for a total of 40,000 shares vest in four equal annual installments, and are exercisable once vested. The first
- (6) installment became exercisable on March 19, 2013, the second installment became exercisable on March 19, 2014, the third installment became exercisable on March 19, 2015, and the fourth installment vests on March 19, 2016.
- The options vest in four equal annual installments, and are exercisable once vested. The first installment became exercisable on March 5,
- (7) 2014, the second installment became exercisable on March 5, 2015, the third installment vests on March 5, 2016, and the fourth installment vests on March 5, 2017.
- The options vest in four equal annual installments, and are exercisable once vested. The first installment became exercisable on March 3,
- (8) 2015, the second installment vests on March 3, 2016, the third installment vests on March 3, 2017, and the fourth installment vests on March 3, 2018.
- (9) The options vest in four equal annual installments beginning on March 11, 2016, and are exercisable once vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.